The S&P 500 is ‘extremely concentrated,' Apollo economist says, warning the best AI investment may not be in the Magnificent 7
It's time to question the soundness of continued zealous investment in the Magnificent Seven, one top economist warns.
The S&P 500 has become 'extremely concentrated,' with the top 10 stocks contributing 54% of the market returns since January 2021, Apollo chief economist Torsten Sløk said in a Friday blog post. With the cluster of tech stocks at the top beginning to unravel, he is pouring cold water on continued aggressive investment in the index and in the Magnificent Seven.
'The textbook idea that the S&P 500 gives you a diversified exposure to risk is just simply no longer the case,' Sløk told Fortune. 'You are very focused and concentrated in a small group of names, in particular in tech, making up such a significant share of your overall risk exposure.'
The top 10 companies in the S&P 500 now prop up 40% of the index's market capitalization—more than 30% of which is from the Mag Seven—meaning the fortune of the markets has become increasingly reliant on investors' optimism in AI. Alphabet's AI rally not only helped mint CEO Sundar Pichai as a billionaire, for example, but the Google parent's earnings beat gave the S&P 500 its fourth consecutive record close on Thursday.
But as the AI bubble swells larger than that of the IT bubble a quarter century ago, as Sløk has previously noted, the extreme hype around the technology risks creating even broader economic consequences than the dot-com crisis. To protect one's individual investments, now is the time to reconsider pouring money into the Mag Seven, Sløk argued.
'One should have some exposure to the S&P 500 and should certainly also have some exposure to AI,' Sløk said. 'But it's very clear that [due to] the market's extreme focus and concentration on this story, this is the time to have a conversation around, What are the things I should be doing with my money?'
The Magnificent Seven becomes Six, becomes Five
Mounting concerns about the ramifications of a growing AI bubble coincide with the unraveling of the Magnificent Seven stocks.
'We're beginning to have conversations about the 'Magnificent Six', maybe it's only five,' Sløk said. 'This is also just telling you that the Magnificent Seven are seven very, very different companies that have very different businesses.'
Popularized in 2023 by Bank of America analyst Michael Hartnett, the 'Magnificent Seven' was meant to bunch together a group of companies alike in their goal of pushing toward an AI future, but the tech firms once in lockstep are beginning to diverge in their levels of success and areas of investment.
Apple, for example, has lagged behind competitors like Microsoft and Meta in developing AI products and services. With its stock down about 12% year-to-date, some market watchers have called for CEO Tim Cook to step down from the company, despite Cook boosting the company's stock price by nearly 1,500% over the past decade-plus.
Tesla has likewise failed to deliver on promises to autonomous driving, continuing this week its streak of sales misses and disappointing quarters. Tesla's stock has fallen nearly 15% in 2025 as investors' confidence in CEO Elon Musk continues to be tested.
Meanwhile, Nvidia this month became the first publicly traded company with a more than $4 trillion valuation as its stock price surged by approximately 1,460% over the past five years. The company expected to continue strong sales growth, despite increasing competitive pressures.
Ahead of next week's earnings reports for Meta, Apple, and Microsoft, analysts are continuing to scrutinize the pricing of these companies' stocks, assessing if there are other options in the tech sector worth buying into.
'AI will continue to have a dramatic impact on all our lives,' Sløk wrote in his blog post. 'But the question remains whether the Magnificent Seven are correctly priced, and if they will even be the best AI investments over the next five to ten years.'
This story was originally featured on Fortune.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio